{
  "id": "5a76072283b0d9ea66000013",
  "type": "yesno",
  "question": "Does armodafinil improve fatigue of glioma patients?",
  "ideal_answer": "No. Eight week course of armodafinil did not improve fatigue or quality of life in glioma patients undergoing radiotherapy. However, this conclusion is based on one identified clinical trial.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26902850"
  ],
  "snippets": [
    {
      "text": "CONCLUSIONS: While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Armodafinil did not significantly improve fatigue or QOL based on the 42-day change in FACIT-F fatigue subscale, FACT-G, CFS, or BFI. Further analysis suggests no difference between the arms even after accounting for the potential bias of missing data. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment was well tolerated with few grade 3 or 4 toxicities.<br><b>CONCLUSIONS</b>: While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Armodafinil did not significantly improve fatigue or QOL based on the 42-day change in FACIT-F fatigue subscale, FACT-G, CFS, or BFI.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D005221",
    "https://meshb.nlm.nih.gov/record/ui?ui=D010361",
    "http://www.biosemantics.org/jochem#4216693",
    "https://meshb.nlm.nih.gov/record/ui?ui=D005910"
  ],
  "exact_answer": "Yes"
}